As BULLISH Ratings Pile Up, NASDAQ: OKYO May Be Set for Another Big Breakoutâ¦.âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ âÍ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â As BULLISH Ratings Pile Up, NASDAQ: OKYO May Be Set for Another Big Breakoutâ¦. Greetings Investors, One question that smart investors will ask about anything before they invest in it is, âWhatâs the demand like?â This is why many biotech companies are aggressively churning out drug candidates for diseases and problems that have high demands. One disease that doesnât get a lot of discussion is dry eye disease.
While itâs not fatal, it is a daily challenge for millions of people leaving them with burning, stinging, or excessive blinking. This can impair routines and activities and be embarrassing. According to Fortune Business Insights, global [Dry Eye Syndrome Market]( size was valued at USD 6.61 billion in 2022 and is projected to grow from USD 7.02 billion in 2023 to USD 11.26 billion in 2030, exhibiting a CAGR of 7.0% during the forecast period. Various environmental and health conditions can cause dry eyes. Too much screen time is a significant risk factor. Screens have become a big part of our world and the issue of dry eyes may only get worse. This makes OKYO Pharma Limited (NASDAQ: OKYO) an exciting company with monstrous growth potential to have your eyes on! This growing biotech company has a $5.50 price target on it and is developing first-in-class pharmaceutical therapies to treat inflammatory eye diseases, including dry eye disease. [www.okyopharma.com]( NASDAQ: OKYO currently has a âSTRONG BUYâ rating at [BarChart.com]( and a âSTAY LONGâ rating at [AmericanBulls.com.]( Not that long ago shares broke out from around $1.20 to over $3 in only weeks, before retracing. The stock certainly knows how to move quickly in the short term. Top-line data from OKYOâs Phase 2 trial is anticipated before the year ends⦠keep an eye out for this!! It could trigger another big breakout!Earlier this year coverage of the company was initiated by Goldman Small Cap Research, who gave it a price target of $5.50! This price target is potentially nearly 200% upside from current levels! INVESTMENT HIGHLIGHTS FROM THE REPORT INCLUDE: - OKYO is poised to emerge as a key player in the Dry Eye Disease (DED) treatment market. Based on its preclinical studies, Goldman Small Cap Research believes OKYO could offer advantages over existing therapies, which are not viewed favorably by clinicians. These include fewer side effects, along with reduced inflammation and pain.
- The ocular company industry and the DED sub- segment, are huge and growing at a rapid rate. The global DED market is expected to reach $6.54 billion in 2027, up from about $5.2 billion in 2019.
- OKYO commenced a Phase II clinical trial with the objective of measuring safety and efficacy of OK-101 in DED patients, along with secondary endpoints such as ocular pain. A serious issue among a number of DED sufferers, there is no FDA approved product for neuropathic pain.
- Top-line data from the trial is scheduled for release by year-end 2023 and serves as a major milestone for OKYO. Goldman Small Cap Research believes it is the catalyst for a re- valuation for the stock and for a mid-tier or top-tier firm to enter into a partnership with OKYO.
- A 6â9-month price target for OKYO is $5.50. This target is based on the NPV of forecasted sales, a discounted price/sales multiple, discounted back five years at a reasonable discount rate. - The ocular treatment segment has garnered major attention. A flurry of M&A has occurred at high valuations, and OKYOâs peers also reflect these high valuation characteristics. Goldman Small Cap Research believes OKYO could emulate this trend in the future.You can read the full report [HERE.]( As the company continues concentrating on the development of its drug candidate OK-101 to treat ocular diseases, it may start getting more Wall Street attention. OK-101 is being developed to treat: - Dry eye (DED) uveitis
- Allergic conjunctivitis
- Ocular pain MORE ABOUT OK-101: OK-101 is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. ChemR23 receptor on leukocytes targeted by OK-101 is also expressed on neurons and glial cells in the dorsal root ganglion and spinal cord. Such patients would benefit from a drug that comprises anti-inflammatory and neuropathic pain-reducing characteristics. The drug candidate has been shown to produce anti-inflammatory and neuropathic pain-reducing activities in mouse models of DED and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid âanchorâ contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment. It wasnât that long ago that the U.S. Food and Drug Administration (FDA) cleared OKYOâs Investigational New Drug (IND) to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of Dry Eye Disease (DED)! This trial is now underway and takes it closer and closer to a possible FDA approval! âOne of the most exciting aspects of this innovative clinical program is that we can get a rapid and informative answer on both safety and efficacy of OK-101 by the end of the year,â said Gabriele Cerrone, Executive Chairman and Founder of OKYO Pharma. âFurthermore, positive results would allow us to expedite the program towards FDA approval by leveraging results from this phase 2 dry eye trial in lieu of one of the two required phase 3 trials needed to support U.S. marketing authorization. OKYO remains well-positioned as novel ophthalmic compounds in large markets represent promising acquisition targets as evidenced by the recent $5.9 billion Iveric deal.â Earlier this year one of the biggest headlines in biotech was the announcement from Astellas Pharma about agreeing to buy U.S. drugmaker Iveric Bio Inc for about [$5.9 billion](. That massive acquisition had closed in July. It is the biggest acquisition for Astellas yet, giving it access to a range of ophthalmology treatmentsâ¦. The sheer magnitude of this deal has emphasized just how important the eye healthcare market is and the potential for OKYO! In Summary⦠OKYO is an emerging player in eye treatment and could be trading at a PREMIUM right now, as it leads the way in eye care advancements. OK-101, the companyâs game-changing drug candidate could put this underfollowed company on the map. To reiterate, top-line data from the companyâs Phase 2 trial is anticipated before the year ends. If OKYOâs OK-101 phase 2 trial is successful, it may serve as one of two required phase 3 studies necessary to support FDA approval! OKYOâs immediate goal is to overcome the limitations of current dry eye treatments with the development of a first-in-class drug that combines both anti-inflammatory and pain-reducing activity. This would be a FIRST! Currently, there is NO FDA-approved topical treatment for ocular pain. Start your research right away! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product youâve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer â Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing âIâ or âweâ or âourâ or âSCDâ refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editorâs, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in OKYO. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding OKYO with a start date of 10/03/2023. SCDâs business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled companyâs website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writersâ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writerâs communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042
© 2023 | All rights reserved.
[Unsubscribe](. [Twitter] [Facebook] [Instagram]